These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 27013515)

  • 1. [-2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first report.
    De Luca S; Passera R; Sottile A; Fiori C; Scarpa RM; Porpiglia F
    BMC Urol; 2016 Mar; 16():14. PubMed ID: 27013515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome.
    Vesely S; Jarolim L; Schmidt M; Minarik I; Dusek P; Babjuk M
    World J Urol; 2013 Apr; 31(2):299-304. PubMed ID: 22684375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detectable Prostate-specific antigen value between 0.01 and 0.1 ng/ml following robotic-assisted radical prostatectomy (RARP): does it correlate with future biochemical recurrence?
    Zakaria AS; Schwartz RN; Hodhod A; Couture F; Tholomier C; Shahine H; Negrean C; Nguyen DD; Zanaty M; Stolzenbach F; Karakiewicz PI; El-Hakim A; Zorn KC
    World J Urol; 2021 Jun; 39(6):1853-1860. PubMed ID: 32696130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology.
    Kang JJ; Reiter RE; Steinberg ML; King CR
    Eur Urol Oncol; 2018 Oct; 1(5):378-385. PubMed ID: 31158076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence.
    Skove SL; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Moreira DM; Freedland SJ
    Urology; 2017 Oct; 108():129-134. PubMed ID: 28735016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of postoperative nadir prostate-specific antigen value by ultrasensitive assay as a predictor of prostate-specific antigen relapse for pathological T3 or positive surgical margins after radical prostatectomy for prostate cancer.
    Yoshida T; Matsuzaki K; Kobayashi Y; Takeda K; Nakayama M; Arai Y; Kakimoto K; Nishimura K
    Int Urol Nephrol; 2012 Apr; 44(2):479-85. PubMed ID: 21822599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early prediction of prostate cancer biochemical recurrence and identification of disease persistence using PSA isoforms and human kallikrein-2.
    Do Carmo Silva J; Vesely S; Luksanova H; Prusa R; Babjuk M
    Tumour Biol; 2021; 43(1):197-207. PubMed ID: 34486998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
    Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database.
    Chang SL; Freedland SJ; Terris MK; Aronson WJ; Kane CJ; Amling CL; Presti JC
    Urology; 2010 Feb; 75(2):439-44. PubMed ID: 19819536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer-results from an international multicenter study.
    Heidegger I; Klocker H; Pichler R; Pircher A; Prokop W; Steiner E; Ladurner C; Comploj E; Lunacek A; Djordjevic D; Pycha A; Plas E; Horninger W; Bektic J
    Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):271-275. PubMed ID: 28322234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.
    Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Sun LL; Moul JW; Freedland SJ
    Int J Urol; 2010 Nov; 17(11):914-22. PubMed ID: 20880361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen.
    Greenberg SA; Washington SL; Lonergan PE; Cowan JE; Baskin AS; Nguyen HG; Odisho AY; Simko JP; Carroll PR
    J Urol; 2021 Sep; 206(3):706-714. PubMed ID: 33905262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.
    Van den Broeck T; van den Bergh RCN; Arfi N; Gross T; Moris L; Briers E; Cumberbatch M; De Santis M; Tilki D; Fanti S; Fossati N; Gillessen S; Grummet JP; Henry AM; Lardas M; Liew M; Rouvière O; Pecanka J; Mason MD; Schoots IG; van Der Kwast TH; van Der Poel HG; Wiegel T; Willemse PM; Yuan Y; Lam TB; Cornford P; Mottet N
    Eur Urol; 2019 Jun; 75(6):967-987. PubMed ID: 30342843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrasensitive prostate specific antigen assay following laparoscopic radical prostatectomy--an outcome measure for defining the learning curve.
    Viney R; Gommersall L; Zeif J; Hayne D; Shah ZH; Doherty A
    Ann R Coll Surg Engl; 2009 Jul; 91(5):399-403. PubMed ID: 19409146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors associated with biochemical recurrence following radical prostatectomy for pathological T2 prostate cancer with negative surgical margins.
    Aoun F; Albisinni S; Henriet B; Tombal B; Van Velthoven R; Roumeguère T
    Scand J Urol; 2017 Feb; 51(1):20-26. PubMed ID: 27910728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.
    Shen S; Lepor H; Yaffee R; Taneja SS
    J Urol; 2005 Mar; 173(3):777-80. PubMed ID: 15711268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.